CUE vs. SGMT, PDSB, ALXO, CRDF, ELUT, PYRGF, MGX, OPTN, RLMD, and ELDN
Should you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Sagimet Biosciences (SGMT), PDS Biotechnology (PDSB), ALX Oncology (ALXO), Cardiff Oncology (CRDF), Elutia (ELUT), PyroGenesis Canada (PYRGF), Metagenomi (MGX), OptiNose (OPTN), Relmada Therapeutics (RLMD), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry.
Sagimet Biosciences (NASDAQ:SGMT) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
Cue Biopharma received 125 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 95.45% of users gave Sagimet Biosciences an outperform vote while only 52.33% of users gave Cue Biopharma an outperform vote.
Sagimet Biosciences currently has a consensus price target of $24.00, indicating a potential upside of 545.16%. Cue Biopharma has a consensus price target of $5.00, indicating a potential upside of 748.90%. Given Cue Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Cue Biopharma is more favorable than Sagimet Biosciences.
87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 17.6% of Sagimet Biosciences shares are held by company insiders. Comparatively, 7.5% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Cue Biopharma had 3 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for Cue Biopharma and 3 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.70 beat Cue Biopharma's score of 0.41 indicating that Sagimet Biosciences is being referred to more favorably in the media.
Sagimet Biosciences has higher earnings, but lower revenue than Cue Biopharma.
Sagimet Biosciences has a beta of 3.6, meaning that its share price is 260% more volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.
Sagimet Biosciences has a net margin of 0.00% compared to Cue Biopharma's net margin of -566.02%. Sagimet Biosciences' return on equity of -20.81% beat Cue Biopharma's return on equity.
Summary
Sagimet Biosciences beats Cue Biopharma on 10 of the 16 factors compared between the two stocks.
Get Cue Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cue Biopharma Competitors List
Related Companies and Tools
